Garg Pushkal

SEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,946

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.23 to $252.22. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,724

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.71 to $250.42. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,150

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $248.69 to $249.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000110 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,336

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 6

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,457

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 5

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,554

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,499

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,863

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,109

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,139

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-24-000098 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,705

F1 · kind: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on October 8, 2024.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 13

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,609

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 12

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,828

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 11

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,070

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 10

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,221

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 9

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,504

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 8

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,633

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 7

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,031

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 6

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,379

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 5

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,548

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,593

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,617

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,634

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,712

F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024.

SEC source: 0001735276-24-000029 · edgardoc.xml · derivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,279

Underlying: Common Stock · 9,279 shares

Expires 2034-03-01

F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vesting in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

SEC source: 0001735276-24-000029 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,417

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

F2 · balance_after: The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 4,751 newly awarded RSUs and 8,666 shares of common stock. The Reporting Person also holds 3,816 unvested RSUs that were previously reported in Table II.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 6

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,666

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 5

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,667

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,684

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,799

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,993

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000017 · edgardoc.xml · derivative · entry 9

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,816

Underlying: Common Stock · 1,908 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F9 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

F9 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

SEC source: 0001735276-24-000017 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001735276-24-000010 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,332

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000010 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,488

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000010 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,160

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000010 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,640

F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 11

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,345

F9 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.20 to $185.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 10

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,585

F9 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.12 to $184.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 9

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,399

F9 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $183.09 to $184.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 8

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,511

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 7

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,675

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $188.14 to $189.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 6

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,690

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $187.04 to $188.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 5

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,776

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $186.03 to $187.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 4

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,721

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $185.02 to $186.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 3

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,314

F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $184.01 to $185.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 2

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,972

F2 · kind: On February 24, 2021, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2020 year-end compensation review. The PSUs vest in separate installments based on the achievement of four specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-quarter of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.

SEC source: 0001735276-23-000079 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,863

F1 · kind: On February 26, 2020, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2019 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of the achievement of the first $2.5 billion in cumulative net product revenues determined in accordance with GAAP based solely upon the sales by the Company, including its affiliates and ex-U.S. distributions, of products discovered/developed by the Company.

SEC source: 0001209191-23-037379 · doc4.xml · derivative · entry 1

Garg Pushkal · CIK 0001829252 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,875

Underlying: Common Stock · 39,875 shares

Expires 2033-06-13

F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.

SEC source: 0001735276-23-000044 · edgardoc.xml · nonDerivative · entry 12

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,345

F7 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.